NCT03852511View on ClinicalTrials.gov

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions
Metastatic CancerEpithelial Tumor
Interventions
BIOLOGICAL

NG-350A

NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.

Trial Locations (5)

10038

Memorial Sloan Kettering Cancer Center (MSKCC), New York

44195

Cleveland Clinic, Cleveland

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

90404

University of California, Los Angeles (UCLA), Santa Monica

Sponsors

Lead Sponsor

Akamis Bio
All Listed Sponsors
lead

Akamis Bio

INDUSTRY

NCT03852511 - First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) | Biotech Hunter | Biotech Hunter